Last updated: July 27, 2026
Horizon Pharma Ireland Ltd. v. Actavis Laboratories UT, Inc. (1:15-cv-07742): Litigation Summary, Patent Issues, and Generic-Entry Risk
Horizon Pharma Ireland Limited sued Actavis Laboratories UT, Inc. for patent infringement in case 1:15-cv-07742. The record ties the dispute to a Paragraph IV-style generic launch challenge framework, with the litigation’s leverage largely determined by (1) the asserted Orange Book patents, (2) whether the case reached judgment or settlement, and (3) whether any final injunction or dismissal narrowed the allowable generic product design or approval timing.
What does Horizon Pharma Ireland Ltd. v. Actavis Laboratories UT cover—case overview and key procedural posture?
Core parties
- Plaintiff: Horizon Pharma Ireland Limited
- Defendant: Actavis Laboratories UT, Inc.
Docket
- Court: U.S. District Court (district and division not determinable from the provided input)
- Case number: 1:15-cv-07742
What typically drives cases with this caption
Litigation against a Paragraph IV generic filer generally centers on:
- One or more Orange Book-listed patents tied to the reference listed drug (RLD)
- A claim that the defendant’s ANDA product would infringe at least one asserted patent
- A downstream commercial risk: whether the court blocks launch or whether settlement permits an “at-risk” or time-limited entry.
What cannot be completed from the provided input
A complete litigation summary requires at least one of the following: asserted patent numbers, the RLD/ANDA product name, the filing date, the asserted claims, and the settlement or judgment date. None of these details are present in the prompt.
Which patents were asserted in 1:15-cv-07742 and what were the infringement theories?
A litigation-level infringement map needs hard identifiers:
- Asserted patent numbers
- Title/subject matter (composition, formulation, method-of-use, manufacturing)
- Claim construction positions and asserted independent/dependent claims
- Infringement basis (literal infringement vs. doctrine of equivalents) and any invalidity challenges.
No patent numbers or claim summaries are included in the provided input. Without them, a precise “patent-by-patent” infringement/validity analysis cannot be produced.
What was the procedural timeline—motions to dismiss, claim construction, summary judgment, trial, and appeal?
A Bloomberg-style litigation timeline requires docket milestones such as:
- Complaint filing date and service
- Answer and invalidity contentions
- Markman/claim construction schedule
- Summary judgment deadlines
- Trial dates (if any)
- Entry of final judgment
- Any Rule 54(b) partial final judgment
- Post-judgment injunction orders
- Federal Circuit appeal filings and dispositions
The input provides only the case number and parties. Without docket events, the timeline cannot be reconstructed accurately.
Did Actavis challenge infringement via invalidity or non-infringement defenses—and which grounds mattered?
Typical generic defenses in Hatch-Waxman patent suits include:
- Invalidity for lack of novelty, obviousness, or enablement under 35 U.S.C. §§ 102/103/112
- Non-infringement based on formulation differences, manufacturing process distinctions, or non-matching method parameters
- Prosecution history estoppel and inequitable conduct arguments (less frequent but possible)
The prompt does not include the defenses pleaded or any court rulings. A defensible analysis cannot be produced without those filings and orders.
How did this litigation affect FDA approval and potential generic launch timing?
Patent cases drive FDA entry via:
- 30-month stay triggered by Paragraph IV notice and ANDA litigation timelines
- Post-litigation outcomes that lift or extend the effective exclusivity window:
- Permanent injunction (launch blocked)
- Limited injunction (claims narrowed to specific conditions)
- Dismissal or finding of non-infringement/invalidity (launch permitted)
- Settlement-driven “carve-outs” and agreed launch dates.
No ANDA product, RLD name, FDA approval status, or settlement/judgment outcome is present in the input. Therefore, launch-timing conclusions would be incomplete.
Was there a settlement or consent judgment—what were the commercial terms and launch carve-outs?
A settlement analysis must cite:
- Settlement agreement date
- Allowed launch date (or payment-for-delay structure if applicable)
- Design-around boundaries (formulation or method-of-use carve-outs)
- Dismissal with or without prejudice
- Whether any stipulations of non-infringement or final validity findings were entered
- Any ongoing royalty or supply arrangement.
The prompt provides no settlement information or docket disposition. A terms-based analysis cannot be completed.
What is the Orange Book status of the asserted patents for the RLD tied to this case?
Orange Book status work requires:
- Identifying the RLD for which Horizon listed patents were asserted
- Listing those patents and their expiration dates
- Identifying any pediatric exclusivity, patent term adjustments, and exclusivity end dates
- Mapping any remaining patents that could block a generic even after one patent is litigated.
None of these inputs are available in the prompt.
How strong is Horizon Pharma’s patent estate in this matter—what did the court find?
Patent strength in litigation is measured by:
- Court rulings at key stages (claim construction, summary judgment, trial)
- Findings on infringement and invalidity
- Any narrowing constructions that preserve patent validity
- Whether the asserted claims survived dispositive motion.
Without rulings or outcomes, no strength assessment can be made without inventing facts.
How does Actavis’s litigation posture compare with other generic challengers against Horizon—what are common outcomes?
Comparative analysis needs:
- Other cases by the same plaintiff against other ANDA filers
- Shared asserted patents and similar infringement/invalidity issues
- Settlement patterns and entry windows.
No comparative case list is present in the prompt.
What generic entry risks exist if a court decision allowed launch—or if the case settled?
Entry risks are typically product-specific and patent-specific:
- Residual enforceable patents after dismissal
- Design-around compliance risk (formulation/process/method parameters)
- Post-launch infringement exposure and willfulness enhanced damages considerations
- Regulatory risk if the ANDA approval depends on specific labeling or BE methodology.
No asserted-patent set or outcome is available in the input.
Key Takeaways
- The provided input identifies the parties and docket number (Horizon Pharma Ireland Limited v. Actavis Laboratories UT, Inc., 1:15-cv-07742), but it does not include the asserted patents, litigation milestones, or final disposition.
- A litigation summary that is accurate at the patent and procedural level cannot be generated without those specific record elements.
FAQs
- What information is needed to summarize a Hatch-Waxman case like 1:15-cv-07742 (patent numbers, claims, and outcome)?
- How do Paragraph IV litigation outcomes typically change 30-month stay timing and FDA launch dates?
- What are the most common invalidity grounds raised in Horizon-style Orange Book patent cases involving generics?
- How do settlements in ANDA patent cases usually structure allowed launch dates and design-around boundaries?
- What court rulings most directly determine infringement and invalidity outcomes in method-of-use vs. formulation patent disputes?
References
No sources were provided, and no cited record details (patent numbers, docket events, orders, or settlements) are available from the prompt to support citation.
